Logo

IBAC

IB Acquisition Corp. Common Stock

IBAC

IB Acquisition Corp. Common Stock • NASDAQ
$10.50 ▲ 0.00% (+0.00)
Market Cap $165.37 M
52w High $11.45
52w Low $10.07
Dividend Yield 0%
P/E 43.75
Volume 1.73K
Outstanding Shares 15.75M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $172.21K ▲ $818.61K ▼ 0% $0.05 ▼ $-172.21K ▼
Q2-2025 $0 $163.485K ▼ $824.126K ▼ 0% $0.052 ▼ $-163.485K ▲
Q1-2025 $0 $176.441K ▲ $907.068K ▼ 0% $0.058 ▼ $-176.441K ▼
Q4-2024 $0 $165.458K ▲ $1.036M ▼ 0% $0.066 ▼ $-165.458K ▼
Q3-2024 $0 $76.379K $1.113M 0% $0.071 $-76.379K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $486.018K ▼ $122.177M ▲ $549.009K ▲ $121.628M ▲
Q2-2025 $627.375K ▼ $121.164M ▲ $355.147K ▼ $120.809M ▲
Q1-2025 $910.193K ▲ $120.832M ▲ $846.324K ▲ $119.985M ▲
Q4-2024 $822.799K ▼ $119.8M ▲ $722.23K ▲ $119.078M ▲
Q3-2024 $876.649K $118.394M $352.354K $118.042M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $818.61K ▼ $-141.357K ▲ $0 ▼ $0 ▲ $-141.357K ▲ $-141.357K ▲
Q2-2025 $824.126K ▼ $-744.189K ▼ $609K ▲ $-147.629K ▼ $-282.818K ▼ $-744.189K ▼
Q1-2025 $907.068K ▼ $-375.235K ▼ $315K ▲ $147.629K ▲ $87.394K ▲ $-375.235K ▼
Q4-2024 $1.036M $-53.85K $0 $0 $-53.85K $-53.85K
Q3-2024 $1.036M $-53.85K $0 $0 $-53.85K $-53.85K

Five-Year Company Overview

Income Statement

Income Statement IB Acquisition Corp. is essentially a shell at this stage, so its income statement is more of an accounting formality than a reflection of a real operating business. The company has no meaningful revenue, no gross profit, and no ongoing operations. Any reported earnings per share or net income figures are likely tied to interest on cash, changes in liabilities, or one‑off accounting items rather than business performance. In short, there is no underlying business engine here yet; the income statement will only become truly informative after a merger with an operating company is completed.

Balance Sheet

Balance Sheet The balance sheet is very small and simple, which is typical for a SPAC outside of the separate IPO trust account. What stands out is that the company is essentially equity‑funded with no reported debt, suggesting a clean and conservative capital structure. At the same time, the asset base is minimal and there are no operating assets like plants, equipment, or working capital, because IBAC does not run a real business yet. The financial picture is that of an empty corporate shell that is structurally ready to host a future operating company but has not done so yet.

Cash Flow

Cash Flow Reported cash flow activity is negligible, again reflecting the lack of operations. There is no meaningful cash being generated from customers and no capital spending because the company has nothing to build or maintain yet. For SPACs, most of the real cash dynamics happen in the IPO trust and through administrative expenses, which are not fully visible in this simplified snapshot. The key cash flow question going forward is how long the existing resources can comfortably cover ongoing SPAC costs while management searches for a merger target, and what the cash position will look like after any redemptions at the time of a deal.

Competitive Edge

Competitive Edge As a SPAC, IBAC’s competitive position is not about products or market share, but about its ability to source and close an attractive merger before its deadline. It competes with other blank‑check companies and traditional capital markets as potential funding options for private businesses. The recent extension of its deadline into 2026 signals that shareholders were willing to grant more time, but it also confirms that a suitable deal has not yet been finalized. In today’s tougher SPAC environment—with more scrutiny from regulators and investors—success will largely depend on the sponsor team’s reputation, deal‑making skills, and their ability to find a target that existing and new shareholders are willing to support.

Innovation and R&D

Innovation and R&D IB Acquisition Corp. itself does not develop products, technology, or intellectual property, so it has no research and development activity of its own. Its role is purely financial: raise capital and then merge with a private company that does have a real business. The detailed discussion in your materials about advanced gene‑circuit therapies and Senti Biosciences refers to a different, earlier IBAC vehicle that already merged and now operates under another name. For this current IBAC, any future innovation profile will be entirely determined by whichever company it ultimately acquires; until then, there is no inherent technological edge or R&D story at the SPAC level.

Summary

IB Acquisition Corp. is a classic early‑stage SPAC: no operating business, no real revenue, a very simple balance sheet, and minimal visible cash flow. Its current financials do not tell a growth or profitability story; they simply show a clean, debt‑free shell waiting for a transaction. The real opportunity and risk lie entirely in the future merger: which company is chosen, how the deal is structured, how many shareholders redeem, and how the combined entity performs. The deadline extension into 2026 buys time but also highlights execution risk if a compelling target proves hard to secure. Until a specific business combination is announced and detailed, analysis is necessarily focused on structure and timing rather than on traditional fundamentals.